News | November 07, 2024
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
US Generics grew 5% to Rs. 467 Crores for the quarter
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
The acquisition is based on an enterprise value of Rs. 1,660 crore
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Subscribe To Our Newsletter & Stay Updated
